Big Tech AI Capex 2026: What $680B in Spending Actually Shows
Big Tech is spending $680B on AI infrastructure in 2026, financed partly with bonds. Here's what the earnings numbers actually show about whether ROI is materializing.
Bull and bear cases, fundamental analysis, and market context for self-directed investors who want rigorous research — not recommendations.
Big Tech is spending $680B on AI infrastructure in 2026, financed partly with bonds. Here's what the earnings numbers actually show about whether ROI is materializing.
The Apple CEO transition to John Ternus sets up three concrete decision windows for AAPL investors. Here's how to read each one before the stock moves.
Sequence of returns risk can silently erase a well-funded retirement. Here's how four defensive strategies compare at 2026 rates — including the TIPS window most retirees are missing.
BWET ETF 2026 has returned 1,300% on Hormuz disruptions — but the futures curve already prices in normalization. Here's what roll costs and short interest reveal.
Goldman, JPMorgan, Citi, Wells Fargo, BofA, and Morgan Stanley all report April 13–15. Here's how to read Q1 2026 bank earnings as macro signal, not stock tip.
Retired into the bull market peak? Sequence of returns risk is no longer hypothetical. Here's what the math actually looks like — and what to do about it.
Private credit is now accessible to retail investors through ETFs, BDCs, and interval funds — each with different liquidity terms and structural risks. See the full breakdown.
Gold hit $5,589 then crashed 27% in seven weeks — while geopolitical risk stayed high. Here's what the stress test reveals about gold investment in 2026.
The ABUSA trade is reshaping 401k international investing. Most retirement savers are already below the diversification floor. Here's the data — and what to audit.
Goldman puts $13/barrel on the energy ETF war premium from Iran. Here's what history says happens when it unwinds — and which ETF carries the most risk.
SpaceX IPO 2026 offers retail investors 3x the usual allocation. Before you read that as an advantage, look at what the deal structure actually does to you.
Cabaletta Bio (CABA) trades at $3 against a $14.50 analyst target. Here are the five catalysts in the next 12 months that will resolve that gap — or close the company.